鼻咽癌放疗后局部复发的治疗

doi:10.3760/cma.j.cn371439-20190926-00007

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (4): 227-230.doi: 10.3760/cma.j.cn371439-20190926-00007

鼻咽癌放疗后局部复发的治疗

沈建军()

中国科学技术大学附属第一医院(安徽省立医院)肿瘤放疗科,合肥 230001

收稿日期:2019-09-26 修回日期:2019-11-11 出版日期:2020-04-08 发布日期:2020-05-26
通讯作者: 沈建军 E-mail:takemeparadise@163.com
基金资助:
中央高校基本科研业务费项目(WK9110000106)

Treatment of local recurrenct nasopharyngeal carcinoma after radiotherapy

Shen Jianjun()

Department of Radiation Oncology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

Received:2019-09-26 Revised:2019-11-11 Online:2020-04-08 Published:2020-05-26
Contact: Shen Jianjun E-mail:takemeparadise@163.com
Supported by:
Fundamental Research Fund for the Central Universities(WK9110000106)

摘要/Abstract

摘要：

精确调强放疗时代鼻咽癌的局部区域控制率非常高,只有10%~20%的患者在初次放疗后会出现局部或淋巴结复发。局部复发鼻咽癌仍然是潜在可治愈的。但局部复发鼻咽癌的再次治疗方案需要优化。根据最新的临床研究证据,可探讨鼻咽癌的复发模式及局部复发鼻咽癌的治疗方案选择。

关键词: 鼻咽肿瘤, 放疗, 肿瘤复发,局部

Abstract:

The local control rate of nasopharyngeal carcinoma in the period of accurate intensity modulated radiotherapy is very high. Only 10% to 20% of the patients will have local or lymph node recurrence after the first radiotherapy. Locally recurrent nasopharyngeal carcinoma is still potentially curable. However, the retreatment of locally recurrent nasopharyngeal carcinoma needs to be optimized. According to the latest clinical research evidence, we explore the recurrence pattern of nasopharyngeal carcinoma and the choice of treatment of locally recurrent nasopharyngeal carcinoma.

Key words: Nasopharyngeal neoplasms, Radiotherapy, Neoplasm recurrence,local

沈建军. 鼻咽癌放疗后局部复发的治疗[J]. 国际肿瘤学杂志, 2020, 47(4): 227-230.

Shen Jianjun. Treatment of local recurrenct nasopharyngeal carcinoma after radiotherapy[J]. Journal of International Oncology, 2020, 47(4): 227-230.

参考文献 25

[1]	Sun XS, Liu SL, Luo MJ , et al. The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012[J]. Int J Radiat Oncol Biol Phys, 2019,105(3):581-590. DOI: 10.1016/j.ijrobp.2019.06.2549.
[2]	Sun XS, Liu DH, Liu SL , et al. Patterns of failure and survival trends in 3,808 patients with stage Ⅱ nasopharyngeal carcinoma diagnosed from 1990 to 2012: a large-scale retrospective cohort study[J]. Cancer Res Treat, 2019,51(4):1449-1463. DOI: 10.4143/crt.2018.688. doi: 10.4143/crt.2018.688
[3]	Yao JJ, Qi ZY, Liu ZG , et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis[J]. Radiother Oncol, 2019,137:137-144. DOI: 10.1016/j.radonc.2019.04.025.
[4]	Miszczyk L, Namysł-Kaletka A, Napieralska A , et al. Stereotactic ablative radiotherapy for prostate cancer-the treatment results of 500 patients and analysis of failures[J]. Technol Cancer Res Treat, 2019,18: 1533033819870815. DOI: 10.1177/1533033819870815.
[5]	Au KH, Ngan RKC, Ng AWY , et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study)[J]. Oral Oncol, 2018,77:16-21. DOI: 10.1016/j.oraloncology.2017.12.004.
[6]	Agas RAF, Yu KKL, Sogono PG , et al. Reirradiation for recurrent nasopharyngeal carcinomas: experience from an academic tertiary center in a low- to middle-income country[J]. J Glob Oncol, 2019,5:1-14. DOI: 10.1200/JGO.18.00191.
[7]	Dionisi F, Croci S, Giacomelli I , et al. Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma[J]. Acta Oncol, 2019,58(9):1238-1245. DOI: 10.1080/0284186X.2019.1622772.
[8]	Kong L, Hu J, Guan X , et al. Phase Ⅰ/Ⅱ trial evaluating carbon ion radiotherapy for salvaging treatment of locally recurrent nasopharyngeal carcinoma[J]. J Cancer, 2016,7(7):774-783. DOI: 10.7150/jca.14399.
[9]	Tian YM, Huang WZ, Yuan X , et al. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy[J]. Oncotarget, 2017,8(26):43450-43457. DOI: 10.18632/oncotarget.15896.
[10]	Gebhardt BJ, Vargo JA, Ling D , et al. Carotid dosimetry and the risk of carotid blowout syndrome after reirradiation with head and neck stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2018,101(1):195-200. DOI: 10.1016/j.ijrobp.2017.11.045. doi: 10.1016/j.ijrobp.2017.11.045
[11]	Li YQ, Tian YM, Tan SH , et al. Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy[J]. J Clin Oncol, 2018,36(9):891-899. DOI: 10.1200/JCO.2017.75.5165. doi: 10.1200/JCO.2017.75.5165
[12]	Pratx G, Kapp DS . Ultra-high-dose-rate FLASH irradiation may spare hypoxic stem cell niches in normal tissues[J]. Int J Radiat Oncol Biol Phys, 2019,105(1):190-192. DOI: 10.1016/j.ijrobp.2019.05.030. doi: 10.1016/j.ijrobp.2019.05.030
[13]	Ng WT, Wong ECY, Cheung AKW , et al. Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-a study by the HKNPCSG[J]. Head Neck, 2019,41(10):3661-3669. DOI: 10.1002/hed.25892. doi: 10.1002/hed.v41.10
[14]	Chan JYW, Wong STS, Wei WI . Surgical salvage of recurrent T3 nasopharyngeal carcinoma: prognostic significance of clivus, maxillary, temporal and sphenoid bone invasion[J]. Oral Oncol, 2019,91:85-91. DOI: 10.1016/j.oraloncology.2019.02.023. doi: 10.1016/j.oraloncology.2019.02.023
[15]	Ganpule A, Patil A, Singh A , et al. Robotic-assisted kidney transplant: a single center experience with median follow-up of 2.8 years[J]. World J Urol, 2019, In press. DOI: 10.1007/s00345-019-02934-0.
[16]	Bickerton R, Ahmed S, Kholief A , et al. Breadth and depth: three-dimensional endoscopic field of view: two-dimensional versus three-dimensional endoscopic field of view[J]. World Neurosurg, 2019,127:e717-e721. DOI: 10.1016/j.wneu.2019.03.247. doi: 10.1016/j.wneu.2019.03.247
[17]	Salom MC, López F, Pacheco E , et al. Salvage surgery in the treatment of local recurrences of nasopharyngeal carcinomas[J]. Acta Otorrinolaringol Esp, 2018,69(6):339-344. DOI: 10.1016/j.otorri.2017.11.006. doi: 10.1016/j.otorri.2017.11.006
[18]	Kang MK, Ahn YC, Park W , et al. High dose radiation therapy concurrent with chemotherapy in locally advanced nasopharynx cancer[J]. Cancer Res Treat, 2003,35(5):391-399. DOI: 10.4143/crt.2003.35.5.391. doi: 10.4143/crt.2003.35.5.391
[19]	Peng H, Tang LL, Liu X , et al. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis[J]. BMC Cancer, 2018,18(1):323. DOI: 10.1186/s12885-018-4268-y. doi: 10.1186/s12885-018-4268-y
[20]	Hui EP, Ma BBY, Loong HHF , et al. Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase Ⅱ correlative study[J]. Clin Cancer Res, 2018,24(5):1030-1037. DOI: 10.1158/1078-0432.CCR-17-1667. doi: 10.1158/1078-0432.CCR-17-1667
[21]	Ng WT, Ngan RKC, Kwong DLW , et al. Prospective, multicenter, phase 2 trial of induction chemotherapy followed by bio-chemoradiotherapy for locally advanced recurrent nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018,100(3):630-638. DOI: 10.1016/j.ijrobp.2017.11.038. doi: 10.1016/j.ijrobp.2017.11.038
[22]	Hsu C, Lee SH, Ejadi S , et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study[J]. J Clin Oncol, 2017,35(36):4050-4056. DOI: 10.1200/JCO.2017.73.3675. doi: 10.1200/JCO.2017.73.3675
[23]	Ma BBY, Lim WT, Goh BC , et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)[J]. J Clin Oncol, 2018,36(14):1412-1418. DOI: 10.1200/JCO.2017.77.0388. doi: 10.1200/JCO.2017.77.0388
[24]	Fang W, Yang Y, Ma Y , et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018,19(10):1338-1350. DOI: 10.1016/S1470-2045(18)30495-9.
[25]	Finazzi T, Rordorf T, Ikenberg K , et al. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy[J]. 2018,18(1):395. DOI: 10.1186/s12885-018-4295-8.

鼻咽癌放疗后局部复发的治疗

Treatment of local recurrenct nasopharyngeal carcinoma after radiotherapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[3]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[4]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[5]	崔腾璐, 孙鹏飞. 鼻咽低级别乳头状腺癌综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(6): 382-384.
[6]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(4): 193-201.
[8]	赵永瑞, 高莹, 陈怡东, 徐建堃. 基于直线加速器的分次立体定向放疗对小体积脑转移瘤的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 138-143.
[9]	黄华玉, 龚虹云, 宋启斌. 胸部放疗联合免疫治疗时代肺炎发生的影响因素[J]. 国际肿瘤学杂志, 2023, 50(2): 102-106.
[10]	曹晓辉, 于荭, 李万湖. 基于CT的影像组学分析在预测和鉴别治疗相关性肺炎中的应用[J]. 国际肿瘤学杂志, 2023, 50(2): 107-111.
[11]	吕璐, 孙鹏飞, 崔腾璐. 子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[12]	陈志明, 陈俊杰, 李李, 丁倩, 韩钰楠, 赵洪瑜. 全外显子组测序筛查食管鳞状细胞癌放疗抵抗相关基因研究[J]. 国际肿瘤学杂志, 2023, 50(10): 592-599.
[13]	车燕敏, 张万红, 吕高峰. 接受挽救手术治疗下咽鳞状细胞癌患者预后影响因素研究[J]. 国际肿瘤学杂志, 2023, 50(1): 12-16.
[14]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[15]	李志磊, 罗加林. 预测局部晚期直肠癌术前同步放化疗敏感性的生物学指标[J]. 国际肿瘤学杂志, 2022, 49(9): 564-567.